

**Supplemental Information****Figure S1: Calcium activation of NUAK1 and NUAK2 in HeLa cells**

**A)** Lysates from HeLa cells treated with 6 $\mu$ M A23187 on the presence or absence of the NUAK1-selective inhibitor HTH-01-015 (10 $\mu$ M for 1 hr) or the NUAK1/NUAK2 inhibitor WZ4003 (10 $\mu$ M for 1hr), probed for phosphor-S445 and total MYPT1. **B)** Lysates from HeLa cells infected with siRNA targeting NUAK2 or non-targeting (-), and treated as above with 6 $\mu$ M A23187 and/or HTH-01-015 (10 $\mu$ M for 1 hr), blotted for phosphor-S445 and total MYPT1. Densitometry of the p-S445 MYPT1 blot shown above. Note that the first 4 lanes are the same images as shown in Main Figure 2C. N=3 experiments.

**Figure S2: Regulation of NUAK1 protein levels by PKC $\alpha$** 

**A)** Immunoblot of NUAK1 protein expression in HeLa cells upon depletion of PKC $\alpha$ , followed by treatment with proteasome inhibitor MG132 (20 $\mu$ M for 5hrs). **B)** Mean and SD fold decrease in NUAK1 protein expression after PKC $\alpha$  depletion in the presence or absence of proteasome inhibitor MG132. N=3. NS = not statistically significant. **C)** Q-PCR measurement of NUAK1 mRNA levels in HeLa cells transfected with either of 2 siRNAs targeting PKC $\alpha$  or non-targeting control. Error bars show SD of technical triplicates. N=2. **D)** Anti-FLAG immunoprecipitates from HeLa cells transfected with FLAG-tagged WT or T211A mutant NUAK1, treated with 0.5 $\mu$ M Gö6976 and/or 3 $\mu$ M A23187, and probed with anti-phospho-AMPK $^{\text{T172}}$  antibody, which cross-reacts with overexpressed NUAK1. N=2.

Figure S1




Figure S2

